Kinetic modeling of the plasma pharmacokinetic profiles of ADAMTS13 fragment and its Fc-fusion counterpart in mice
Introduction: Fusion of the fragment crystallizable (Fc) to protein therapeutics is commonly used to extend the circulation time by enhancing neonatal Fc-receptor (FcRn)-mediated endosomal recycling and slowing renal clearance. This study applied kinetic modeling to gain insights into the cellular p...
Main Authors: | Heechun Kwak, Min-Soo Kim, Suyong Kim, Jiyoung Kim, Yasunori Aoki, Suk-Jae Chung, Hyun-Ja Nam, Wooin Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1352842/full |
Similar Items
-
ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
by: Quintijn Bonnez, et al.
Published: (2023-09-01) -
Anti-ADAMTS13 Autoantibodies: From Pathophysiology to Prognostic Impact—A Review for Clinicians
by: Cristina Dainese, et al.
Published: (2023-08-01) -
ADAMTS-13 gene expression in antiphospholipid syndrome
by: Veysel Sabri Hançer, et al.
Published: (2011-08-01) -
ADAMTS-13 gene expression in antiphospholipid syndrome
by: Veysel Sabri Hançer, et al.
Published: (2011-09-01) -
Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing
by: Eleni Gavriilaki, et al.
Published: (2021-05-01)